598 related articles for article (PubMed ID: 16467118)
21. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
22. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.
Biswas DK; Iglehart JD
J Cell Physiol; 2006 Dec; 209(3):645-52. PubMed ID: 17001676
[TBL] [Abstract][Full Text] [Related]
23. Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation.
Yang X; Yang S; McKimmey C; Liu B; Edgerton SM; Bales W; Archer LT; Thor AD
Carcinogenesis; 2010 Apr; 31(4):695-702. PubMed ID: 20067990
[TBL] [Abstract][Full Text] [Related]
24. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
[TBL] [Abstract][Full Text] [Related]
25. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course.
Yoder BJ; Tso E; Skacel M; Pettay J; Tarr S; Budd T; Tubbs RR; Adams JC; Hicks DG
Clin Cancer Res; 2005 Jan; 11(1):186-92. PubMed ID: 15671545
[TBL] [Abstract][Full Text] [Related]
26. Phorbol ester and epidermal growth factor receptors in human breast cancer.
Wyss R; Fabbro D; Regazzi R; Borner C; Takahashi A; Eppenberger U
Anticancer Res; 1987; 7(4B):721-7. PubMed ID: 3499860
[TBL] [Abstract][Full Text] [Related]
27. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression.
Miller DL; el-Ashry D; Cheville AL; Liu Y; McLeskey SW; Kern FG
Cell Growth Differ; 1994 Dec; 5(12):1263-74. PubMed ID: 7696175
[TBL] [Abstract][Full Text] [Related]
28. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
29. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I
Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434
[TBL] [Abstract][Full Text] [Related]
30. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
31. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
Broom RJ; Tang PA; Simmons C; Bordeleau L; Mulligan AM; O'Malley FP; Miller N; Andrulis IL; Brenner DM; Clemons MJ
Anticancer Res; 2009 May; 29(5):1557-62. PubMed ID: 19443366
[TBL] [Abstract][Full Text] [Related]
32. Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2.
Cui X; Lazard Z; Zhang P; Hopp TA; Lee AV
Oncogene; 2003 Oct; 22(44):6937-41. PubMed ID: 14534541
[TBL] [Abstract][Full Text] [Related]
33. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
34. Obesity and risk of the less commonly diagnosed subtypes of breast cancer.
Stark A; Schultz D; Kapke A; Nadkarni P; Burke M; Linden M; Raju U
Eur J Surg Oncol; 2009 Sep; 35(9):928-35. PubMed ID: 19121564
[TBL] [Abstract][Full Text] [Related]
35. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
Niu G; Carter WB
Cancer Res; 2007 Feb; 67(4):1487-93. PubMed ID: 17308086
[TBL] [Abstract][Full Text] [Related]
36. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
37. [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].
Wang B; Guan ZZ; Liu DG; Lin TY; Zhang L; Xia ZJ; Teng XY
Ai Zheng; 2004 Dec; 23(12):1710-3. PubMed ID: 15601567
[TBL] [Abstract][Full Text] [Related]
38. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
39. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
40. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
Saji S; Omoto Y; Shimizu C; Warner M; Hayashi Y; Horiguchi S; Watanabe T; Hayashi S; Gustafsson JA; Toi M
Cancer Res; 2002 Sep; 62(17):4849-53. PubMed ID: 12208729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
